PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
148 hedge funds and large institutions have $332M invested in PDL BioPharma, Inc. in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 65 reducing their positions, and 20 closing their positions.
837% more call options, than puts
Call options by funds: $356K | Put options by funds: $38K
6% less funds holding
Funds holding: 157 → 148 (-9)
24% less capital invested
Capital invested by funds: $438M → $332M (-$106M)
35% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 20
42% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 65
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$1.79M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.62M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.48M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.46M |
| 5 |
CEP
Chicago Equity Partners
Chicago,
Illinois
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.23M |
| 2 |
BlackRock
New York
|
-$4.2M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.23M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$2.93M |
| 5 |
Morgan Stanley
New York
|
-$2.77M |
PDLI Hedge Fund Activity: Q2 2019 in Review
148 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q2 2019, worth a combined $332M — down 24% from $438M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of PDLI and 13 opened new positions — a net loss of 7 holders — while 65 trimmed existing stakes and 38 added.
The largest buyer was Nuveen, opening a new position worth an estimated $1.79M. The largest seller was Vanguard Group, cutting an estimated $4.23M.
- 148 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q2 2019, down from 157 in Q1 2019.
- Funds reported $332M of PDL BioPharma, Inc. stock for Q2 2019, down 24% quarter-over-quarter.
- 13 funds opened new PDL BioPharma, Inc. positions in Q2 2019 and 20 closed out, a net change of -7 holders.
- The largest PDL BioPharma, Inc. buyer in Q2 2019 was Nuveen, an estimated $1.79M added.
- The largest PDL BioPharma, Inc. seller in Q2 2019 was Vanguard Group, an estimated $4.23M sold.
Based on aggregated 13F filings for Q2 2019.